Ikena Oncology EBITDA 2021-2025 | IMA
Ikena Oncology ebitda from 2021 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Ikena Oncology Annual EBITDA
(Millions of US $) |
| 2024 |
$-60 |
| 2023 |
$-76 |
| 2022 |
$-70 |
| 2021 |
$-34 |
| 2020 |
$-44 |
Ikena Oncology Quarterly EBITDA
(Millions of US $) |
| 2025-03-31 |
$-11 |
| 2024-12-31 |
$-13 |
| 2024-09-30 |
$-13 |
| 2024-06-30 |
$-17 |
| 2024-03-31 |
$-18 |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-20 |
| 2023-06-30 |
$-19 |
| 2023-03-31 |
$-16 |
| 2022-12-31 |
$-15 |
| 2022-09-30 |
$-18 |
| 2022-06-30 |
$-21 |
| 2022-03-31 |
$-17 |
| 2021-12-31 |
$3 |
| 2021-09-30 |
$-14 |
| 2021-06-30 |
$-13 |
| 2021-03-31 |
$-10 |
| 2020-12-31 |
$-34 |
| 2020-09-30 |
$-7 |
| 2020-06-30 |
$-5 |
| 2020-03-31 |
$-7 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.066B |
$0.009B |
|
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.
|
